In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Taro Pharmaceutical Industries Ltd. (TARO), with a price target of $115. The company’s shares closed on Friday at $90.84.
“Valuation methodology, risks and uncertainties. We ascribe a price objective of $115 per share, based on a forward EPS multiple of 12.8x applied to our current fiscal 2020 EPS forecast of $8.98 per share.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -5.0% and a 27.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Taro Pharmaceutical Industries Ltd. is a Moderate Buy with an average price target of $115.
See today’s analyst top recommended stocks >>
Taro Pharmaceutical Industries Ltd.’s market cap is currently $3.54B and has a P/E ratio of 12.60. The company has a Price to Book ratio of 1.93.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing, and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada, and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.